Member Info for GraphiteTech

I know its quite mad really. These levels may look very very cheap after the next RNS.

The 1.724 sells are buys, come on guys I got one of them, lets club together for a blue finish. Reckon it is 250k away!

Wanted to round off to a nice number, last 100k showing to be a sell on LSE though. Naughty.

Come on N4 get out a news piece drawing attention to the reformulated tablet, its on a plate for massive publicity at the moment. They produced something in May when a Viagra patch was muted so a comment and bullish statement on our delivery system ED drug would be great now.

Lot of buys but not moving, games afoot. Likely a delayed sell or general MM games?

someuwin9 Sep '16 - 08:58 - 430 of 430 0 0 This has all the ingredients for creating lifechanging returns... * Ultra low current valuation. * Clear path to becomming GBP100m++ company. * CEO who has previously had success with a similar business model. * Working with successful drugs proven to be safe and effective. * Short and cheap development cycle. * Two unique technology platforms. * Targetting drugs and vaccines (50 potential products identified) * Multiple opportunities for major pharma partnering. ...But remember - the BIG returns come to those who buy at these levels and hold as the company grows.

No sells yet across LSE/ISDX

If you want them under 2p this could be your last chance.

Its very tightly held, months of consolidation around 1.4-1.6 seems to have led to a lot of stock going into sticky hands. There are a lot of holders with 2m+ shares.

100% correct I reckon we should have a value of c£20m at least for N4 now, perhaps higher.

Ivan. First deal unlocks the rest. You have forgotten more about pharma than I will ever know! Could you post a bit of info for the new investors please.

Theobald hopes initially to garner enough cash to fund work on other reformulation targets - he believes there are at least 50 drugs coming off patent that could be improved using the N4 platform.

Was from May. Opal is part of N4 and the ex GSK patent lawyer is part of Opal. Guys the clues have been written all over this for months but apart from a few die hard supporters there has been little interest. If N4 listed today I expect it would achieve a £20m mcap, if FUM goes to £150m mcap I expect the appetite a listed N4 or RTO onto ONZ would be massive. Brokers would have no issue pricing the IPO at £30m. Add in a JV for sildenafil and well call your own price.

Read this, bear in mind we have an ex Boots Pharma top man in the appointment the other day who is also head of drug development of a £1bn company, our connections to the top table of pharma are not in question; Now back to that patent point. It is not the fact that N4 filed 45 patents protecting this reformulation that really stands out. It is the lawyer who made those filings that catches the eye. He is Peter Lawton, ex-legal counsel for GlaxoSmithKline (GSK), who now runs his own company, called Opal IP. Lawton’s previous work helped maintain and extend the lifespan of big sellers such as the antibiotic Augmentin and Paxil, an antidepressant, which literally added billions to GSK’s top line. That expertise in patent law counts for a lot when it comes to licensing your technology to Big Pharma, said Theobald. “The people who win at this game are not the best re-formulaters; the people who win are the ones with the strongest patents,” he explained. Tentative talks are just about to begin with companies interested in reformulating sildenafil.

Again apologies if its old news for some but very important for new investors-- http://www.proactiveinvestors.co.uk/companies/news/126256/n4-pharma-reveals-huge-potential-of-reformulation-game-126256.html

Is not a fantasist either. He's put his hard cash behind the ONZ share price and was buying in the market up to 1.7-1.8p. His record is second to none and previously took an AIM reformualtion company that specialised in ibuprofen of all things from zero to £100m. He left that company to start N4 and his words 'to do something better'.

http://www.derbytelegraph.co.uk/kissing-frogs-paved-way-pound-60m-drugs-palace/story-29014339-detail/story.html N4 Pharma: Has kissing frogs paved the way for a £60m drugs palace? By Derby Telegraph | Posted: April 01, 2016 By Paul Whyatt 0 COMMENTS 11 SHARES image: http://www.derbytelegraph.co.uk/images/localworld/ugc-images/276250/Article/images/29014339/13592902-large.jpg Nigel Theobald's firm N4 Pharma specialises in the reformulation of drugs such as Viagra. Nigel Theobald's firm N4 Pharma specialises in the reformulation of drugs such as Viagra. Comments (0) "WHAT we've done is put the foundations down for what has the potential to become a big palace. What we've now got to do is build it a wing at a time." These words from Nigel Theobald suggest the future of N4 Pharma - the Chellaston-based company he founded in 2014 - is an exciting one. N4 Pharma describes itself as a "specialist pharmaceutical reformulation company". In short, it helps create new versions of existing drugs. Since its creation, the company has been developing proof of concept data for a range of drugs with poor solubility, including a faster-acting version of sildenafil - better known as Viagra – and a single dose hepatitis B vaccine. At the same time, the company has sought partnerships with pharmaceutical companies and biotechnology firms to take these products to regulatory approval. Now, following two "major" announcements, N4 Pharma is tweaking its strategy. The first announcement came on March 1 – this being the news that Nigel had sold 49% of N4 Pharma to Onzima Ventures. The deal saw N4 receive £41,000 in cash from the investment company, which has also provided a loan facility of £209,000 to N4 for the development of its business. A second announcement the following week saw N4 reveal it had expanded its intellectual property portfolio, buying rights for a wide range of patents from Scotland-based Opal IP Ltd. N4 bought a range of patents covering new uses and formulations of many leading off-patent or soon-to-come-off-patent drugs. Nigel said the developments would see the company become "more focused" on securing patents. He said: "The deal with Opal IP is going to give us access to a whole range of different patents for reformulating existing drugs. "That's what we're about. Can we take a formulation and improve it – like what we're doing with fast-acting Viagra? It kicks in after an hour. By owning the patent for that drug, we can make it quicker or even make it last longer. It's just about changing the profile a bit to improve its solubility. "All these patents that belonged to Opal are now with our company and, having invested in the top intellectual property, the next step is to go on and get investment by setting up companies that will be part-owned by N4 and the new investors. "Take Viagra – if we

You need to do a bit of research and read a bit about the company. We not only have the ED drug that is furthest advanced but patents over a whole host of drugs that are securely protected due to GSK ex patent-lawyer doing all the work via Opal. We have a antibiotics section, statins, innoculation and many more all protected and awaiting development. NT really has stolen march on the competition. Likely progress is a JV for the sildenafil reformulation. Then the cash from that unlocks the rest of the portfolio. NT stated its a different way of making a small pharma company a very big one in a short period of time, he's also quoted stating we have (n4) £500m mcap potential in the next few years. £3m/£500m thats 166X..... I would be happy with half of that. LOL.

Similar potential yes, except the mcap here is £3m not £85m like FUM. Risk/reward? I also think FUM is still under valued. That tells you the potential I think we have here.

Highest ever close. They also have a substantial warrant bank which could well pay dividends if a commodities rally continues through to 2017.